PROFILE in Biological Technology

PDHI Launches Short Form of Its ConXus Profile Health Assessment

BERNARDSVILLE, N.J., March 16 /PRNewswire/ -- Protocol Driven Healthcare , Inc. (PDHI) now offers a short form of its health risk assessment (HRA), the ConXus(R) Profile. The shorter format facilitates completion by populations with low literacy and reduces processing costs of paper assessments...

Bluegiga Provides Health Device Profile for its Bluetooth OEM Modules

CONTINUA WINTER SUMMIT and TOKYO, February 4 /PRNewswire/ -- Bluegiga announced today that its OEM Bluetooth modules are now available with Bluetooth Health Device Profile (HDP). The Health Device profile is integrated into Bluegiga's iWRAP firmware, running inside the Bluegiga module, signifi...

Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial

AMD Patients Treated with POT-4 Demonstrate No Adverse Toxic Effects ATLANTA, Nov. 10 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), presented Phase I data last week during the...

OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc.

VANCOUVER, British Columbia, Oct. 28 /PRNewswire-FirstCall/ -- ProtoKinetix Inc. (OTC Bulletin Board: PKTX), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)), announced today that OTC Financial Network (OTCFN), a divi...

Nebulized Formoterol Fumarate Has Comparable Pharmacokinetic and Pharmacodynamic Profile to Dry Powder Formulation

- Data from two clinical trials presented at International ATS Conference - NAPA, Calif., May 20 /PRNewswire/ -- Data presented today at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist(TM) Inhalation Solution (formoterol fumarate inhalation soluti...

Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in World's Largest Stent Registry

OLYMPIA Launch Phase Results Show Positive Outcomes in Diabetic Patients NATICK, Mass. and VIENNA, Austria, Sept. 2 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced one-year results from the European and Intercontinental launch phases of its TAXUS OLYMPIA r...

Metametrix Introduces the New TRIAD(SM) Bloodspot Profile

The Power of the TRIAD Now Available with a Non-Invasive Collection Duluth, Ga., March 31 /PRNewswire/ -- Are you a practitioner with limited access to blood draw facilities? Do you have patients that resist testing if a blood draw is required? Are you constantly looking for ways to make test...

MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile

ANN ARBOR, Mich., Nov. 21 /PRNewswire/ -- MichBio, the association for Michigan's biosciences industry, welcomed nearly 500 biosciences professionals and service providers to its fourth annual Expo on Tuesday and Wednesday of this week at the Rock Financial ShowPlace in Novi, MI. The MichBio Expo...

Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile

- Marine omega-3 phospholipids in NKO(R) outperform established nutraceutical and pharmaceutical omega-3 formulations - - Study results used to direct Acasti Pharma's prescription drug program - LAVAL, QC, Nov. 19 /PRNewswire-F...

Clarient to Commercialize Novel Breast Cancer Profile

Clarient Insight(TM) Dx Breast Cancer Profile Represents First Molecular Test Applicable to All Stages of Operable Breast Cancer ALISO VIEJO, Calif., Jan. 9 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT ), a premier technology and services resource for pathologists, oncologist...

Entrepreneurial Profile Kelly Hansen, CEO of Neohapsis, Inc.

Kelly Hansen. Source: Teresa Esser. Those who venture into the conference room at Neohapsis, Inc. are greeted with a huge black and white poster depicting Kelly Hansen as an entrepreneurial superhero. Created by an illustrator for Marvel Comics, the full color version of the poster is located...

Entrepreneurial Profile Carol Bartz, CEO of Autodesk, shares secrets of success

Carol Bartz Madison, Wis. Carol Bartz, the CEO of Autodesk, was inducted into the University of Wisconsin Madison's Entrepreneur Hall of Fame on Tuesday. Bartz graduated with a UW-Madison computer science degree in 1971. The honor was bestowed by the Weinert Center for Entrepreneurshi...

Thermal Cycling Profile for Standard PCR

Initial denaturation It is very important to denature the template DNA completely. Initial heating of the PCR mixture for 2 minutes at 9495C is enough to completely denature complex genomic DNA so that the primers can...

Untangling the Web: Northwoods Software in profile

Milwaukee Within the ever-expanding realm of content management systems (CMS) providers, Northwoods Software sets itself apart by keeping things simple for clients. Forget the gearhead techno-speak. The Milwaukee area firm is about helping people solve communications and business issues throug...

NeurogesX Reports Second Quarter 2009 Results

...ial to deliver therapeutic efficacy with a potentially improved side effect profile and possible abuse-deterrent attributes. Conference C...rategies to obtain reimbursement for end-users of Qutenza; the tolerability profile and/or benefits of NeurogesX' product candidates; expectations regarding ex...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

...stract on the CAPACITY data, focused on the safety profile of pirfenidone, has been accepted for an oral pres...wo additional abstracts on the topics of the PK/PD profile (#1594) and the viral resistance profile (#1585) of the INFORM-1 regimen have been accepted...

SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

...f the OncoCarta panel. OncoCarta is a comprehensive multi-gene panel available for profiling rare somatic mutations. It enables researchers to rapidly profile genetic changes associated with tumor initiation and progression. The company expects to add more oncogenes and mutations to the OncoCarta panel in th...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

...nt stent features BSC's proprietary platinum chromium alloy, which is designed to enable thinner stent struts, increased flexibility and a lower stent profile while improving radial strength, recoil and radiopacity. In addition, the TAXUS Element stent platform incorporates new balloon technology intended to...

iCardiac Expands Sales and Marketing Team

...afety markers that have been accepted and used as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large an...

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia

...in-resistant Staphylococcus aureus and other bacterial infections. Radezolid has been shown to be efficacious and appears to have a favorable safety profile compared to other oxazolidinone compounds. We are looking forward to progressing the development of radezolid with the intravenous formulation in a mo...

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

... lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tu...

Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level

...s developing a portfolio of highly-potent orally-available inhibitors of the hypoxia signalling pathway. The lead compound shows an excellent in vivo profile and is expected to move into formal preclinical development this year. Further information is available at http://www.elarapharma.com . ...

SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS

... Sweet Enhancers will enable us to help our clients improve the nutritional profile of their products, without compromising on taste. We thus expect these inno...re information, please visit www.senomyx.com . Firmenich Company profile Firmenich is the largest privately-owned company (No.2 worldwide) i...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

...ocols that are intended to form the basis for a new drug application. Final marketing approval depends on the results of efficacy, the adverse event profile and an evaluation of the benefit/risk of treatment demonstrated in the Phase 3 trial. The SPA agreement may only be changed through a written agreemen...

Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia

...avin continued, "We remain encouraged by the supportive comments made by AIDAC committee members in June relative to their positive view of the safety profile of Restanza, the therapeutic need for more effective treatments for CAP and their interest in seeing the Company pursue further development. We contin...

NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results

... the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; the timing and size of potential product launch of Qutenza; the tolerability profile and/or benefits of NeurogesX' product candidates and potential development partners for NeurogesX' early-stage products. Such statements are based on...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

... monkeys). At the 13-week interim, the toxicology profile of ANA598 in both species was very favorable. A p...from the 26-week study in rats indicates a similar profile to that seen in rats at 13 weeks, in which the onl...rters of 2010; (iv) the antiviral and tolerability profile of ANA598 seen to date, which may not be duplicate...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

... monkeys). At the 13-week interim, the toxicology profile of ANA598 in both species was very favorable. Whi...from the 26-week study in rats indicates a similar profile to that seen in rats at 13 weeks, in which the onl...ons into 2011; (ii) the antiviral and tolerability profile of ANA598, which may not be duplicated in future c...

Atherotech Taps Canyons Medical Center Director, Lipidologist as Chief Medical Officer

...ll lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recom..., which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessar...

Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis

...th (Lilac Petal Study) results, a favorable safety profile and clinically meaningful efficacy have again been....0% femur, -1.6% spine). The 150 mg once daily BMD profile in this Lilac Petal Study is consistent with that ...nsiderable improvement on the Endometriosis Health profile (EHP-5), a validated endometriosis-specific scale ...

Sanofi-aventis Announces Second Quarter 2009 Results

... a leading diversified global healthcare company, with a sustainable growth profile by 2013". (3) Closing expected in Q3 2009 (4) Adjusted EPS excl...ent expiries and also providing more sustainable growth with a reduced risk profile as of 2013. Our target efficiency savings of 2 billion euros and the...

iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies

...cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large an...

SAFC Biosciences(R) Defines Hydrolysate Components That Enhance Chinese Hamster Ovary (CHO) Cell Line Protein Production

... an ideal method for biopharmaceutical manufacturers to increase process consistency and reproducibility, while mimicking the productivity and quality profile results from their current hydrolysate-containing processes, is to fully characterize and define those components contained within them. As a result o...

Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4

...s lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tum...

NeoGenomics Reports Second Quarter 2009 Results

... on the company, investor presentations, and more. Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at http://www.hawkassociates.com or from the American Microcap Institute at http://www.am...

Digitas Health Expands Adding Two Key Locations

...sitioned to the role from parent company Digitas, where he had worked for a decade as the relationship creative lead for many of the company's highest profile clients in the automotive and financial services industries. Additionally, as creative director for the Digital Solutions Group at Prodigious, a Digi...

PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2

...n the Massachusetts General Hospital Cancer Center. "If shown to be efficacious, we believe that its oral administration and generally well-tolerated profile could make PTC299 an especially appealing treatment approach for NF2 patients with growing vestibular schwannomas." The new PTC299 clinical stu...

Spectrum Announces Fetal Bovine Serum Product Line

...rce for life science products", says Dr. Arnie Aistars, Chemicals Product Manager at Spectrum. He adds, "We are committed to increasing our profile in the life sciences and biotechnology markets and now have a great foundation on which to build". About Spectrum Chemicals & Laborator...

Anesiva Receives NASDAQ Delisting Staff Determination Letter

...on in opioid medication consumption compared to placebo (p=0.005). The Phase 3 TKA trial, known as ACTIVE-2, also showed that Adlea's safety profile of adverse events, wound healing, and wound sensory function were similar to placebo over the study duration. Forward-Looking Statements ...

Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration

... day, and at all time points in between (2.5, 5.0, 7.5, 10.0, and 12.0 hours). Safety was also evaluated during the study. The adverse event profile for Vyvanse was similar to other currently marketed stimulants. The most frequently reported adverse events (greater than or equal to 10 percent) in ...